[{"A. PROTOCOL INFORMATION": {"A.1:Member State Concerned": "Sweden - MPA", "A.2:EudraCT number": "2015-001314-10", "A.3:Full title of the trial": "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids", "A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language": "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps", "A.4.1:Sponsor's protocol code number": "EFC14280", "A.5.3:WHO Universal Trial Reference Number (UTRN)": "U1111-1170-7180", "A.7:Trial is part of a Paediatric Investigation Plan": "No", "A.8:EMA Decision number of Paediatric Investigation Plan": ""}, "B. SPONSOR INFORMATION": {"B.1.1:Name of Sponsor": "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT", "B.1.3.4:Country": "France", "B.3.1 and B.3.2:Status of the sponsor": "Commercial", "B.4.1:Name of organisation providing support": "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT", "B.4.2:Country": "France", "B.5.1:Name of organisation": "Sanofi AB", "B.5.2:Functional name of contact point": "Country Team Manager Sweden", "B.5.3.1:Street Address": "Box 30052", "B.5.3.2:Town/ city": "Stockholm", "B.5.3.3:Post code": "104 25", "B.5.3.4:Country": "Sweden", "B.5.4:Telephone number": "+ 46 8 634 5000", "B.5.5:Fax number": "+ 46 8 634 5001", "B.5.6:E-mail": "clinicaltrials.sweden@sanofi.com"}, "C. APPLICANT IDENTIFICATION": {}, "D. IMP IDENTIFICATION": {"D.1.2 and D.1.3:IMP Role": "Test", "D.2.1:IMP to be used in the trial has a marketing authorisation": "No", "D.2.5:The IMP has been designated in this indication as an orphan drug in the Community": "No", "D.2.5.1:Orphan drug designation number": "", "D.3.1:Product name": "dupilumab", "D.3.2:Product code": "SAR231893", "D.3.4:Pharmaceutical form": "Solution for injection in pre-filled syringe", "D.3.4.1:Specific paediatric formulation": "No", "D.3.7:Routes of administration for this IMP": "Subcutaneous use", "D.3.8:INN - Proposed INN": "Dupilumab", "D.3.9.2:Current sponsor code": "SAR231893", "D.3.9.3:Other descriptive name": "REGN668", "D.3.9.4:EV Substance Code": "SUB88511", "D.3.10.1:Concentration unit": "mg/ml milligram(s)/millilitre", "D.3.10.2:Concentration type": "equal", "D.3.10.3:Concentration number": "150", "D.3.11.1:Active substance of chemical origin": "No", "D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)": "Yes", "D.3.11.3:Advanced Therapy IMP (ATIMP)": "No", "D.3.11.3.1:Somatic cell therapy medicinal product": "No", "D.3.11.3.2:Gene therapy medical product": "No", "D.3.11.3.3:Tissue Engineered Product": "No", "D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)": "No", "D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product": "No", "D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy": "No", "D.3.11.5:Radiopharmaceutical medicinal product": "No", "D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)": "No", "D.3.11.7:Plasma derived medicinal product": "No", "D.3.11.8:Extractive medicinal product": "No", "D.3.11.9:Recombinant medicinal product": "Yes", "D.3.11.10:Medicinal product containing genetically modified organisms": "No", "D.3.11.11:Herbal medicinal product": "No", "D.3.11.12:Homeopathic medicinal product": "No", "D.3.11.13:Another type of medicinal product": "No", "D.8.1:Is a Placebo used in this Trial?": "Yes", "D.8.3:Pharmaceutical form of the placebo": "Solution for injection in pre-filled syringe", "D.8.4:Route of administration of the placebo": "Subcutaneous use"}, "E. GENERAL INFORMATION ON THE TRIAL": {"E.1.1:Medical condition(s) being investigated": "Bilateral nasal polyposis", "E.1.1.1:Medical condition in easily understood language": "Bilateral nasal polyposis", "E.1.1.2:Therapeutic area": "Diseases [C] - Ear, nose and throat diseases [C09]", "E.1.2:Version": "19.0", "E.1.2:Level": "PT", "E.1.2:Classification code": "10028756", "E.1.2:Term": "Nasal polyps", "E.1.2:System Organ Class": "10038738 - Respiratory, thoracic and mediastinal disorders", "E.1.3:Condition being studied is a rare disease": "No", "E.2.1:Main objective of the trial": "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective.", "E.2.2:Secondary objectives of the trial": "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA).", "E.2.3:Trial contains a sub-study": "No", "E.3:Principal inclusion criteria": "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\n-Signed written informed consent.", "E.4:Principal exclusion criteria": "- Patients <18 years of age.\r\n- Patient who has been previously treated in dupilumab studies.\r\n- Patient who has taken:\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r\n     -Antrochoanal polyps,\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\n     -Ongoing rhinitis medicamentosa,\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener\u2019s granulomatosis),Young\u2019s syndrome, Kartagener\u2019s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\n- Patients receiving concomitant treatment prohibited in the study.\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\n- Known or suspected history of immunosuppression.\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed.", "E.5.1:Primary end point(s)": "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)", "E.5.1.1:Timepoint(s) of evaluation of this end point": "1-2-3 : From baseline to Week 24", "E.5.2:Secondary end point(s)": "1- Change from baseline in TSS\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)", "E.5.2.1:Timepoint(s) of evaluation of this end point": "1-2-3-4-5 : From baseline to Week 24\r\n6: 52 weeks\r\n7-8-9-10 : From baseline to Week 52", "E.6.1:Diagnosis": "No", "E.6.2:Prophylaxis": "No", "E.6.3:Therapy": "Yes", "E.6.4:Safety": "Yes", "E.6.5:Efficacy": "Yes", "E.6.6:Pharmacokinetic": "Yes", "E.6.7:Pharmacodynamic": "Yes", "E.6.8:Bioequivalence": "No", "E.6.9:Dose response": "Yes", "E.6.10:Pharmacogenetic": "Yes", "E.6.11:Pharmacogenomic": "Yes", "E.6.12:Pharmacoeconomic": "Yes", "E.6.13:Others": "No", "E.7.1:Human pharmacology (Phase I)": "No", "E.7.1.1:First administration to humans": "No", "E.7.1.2:Bioequivalence study": "No", "E.7.1.3:Other": "No", "E.7.1.3.1:Other trial type description": "", "E.7.2:Therapeutic exploratory (Phase II)": "No", "E.7.3:Therapeutic confirmatory (Phase III)": "Yes", "E.7.4:Therapeutic use (Phase IV)": "No", "E.8.1:Controlled": "Yes", "E.8.1.1:Randomised": "Yes", "E.8.1.2:Open": "No", "E.8.1.3:Single blind": "No", "E.8.1.4:Double blind": "Yes", "E.8.1.5:Parallel group": "Yes", "E.8.1.6:Cross over": "No", "E.8.1.7:Other": "No", "E.8.2.1:Other medicinal product(s)": "No", "E.8.2.2:Placebo": "Yes", "E.8.2.3:Other": "No", "E.8.2.4:Number of treatment arms in the trial": "3", "E.8.3:The trial involves single site in the Member State concerned": "No", "E.8.4:The trial involves multiple sites in the Member State concerned": "Yes", "E.8.4.1:Number of sites anticipated in Member State concerned": "3", "E.8.5:The trial involves multiple Member States": "Yes", "E.8.5.1:Number of sites anticipated in the EEA": "18", "E.8.6.1:Trial being conducted both within and outside the EEA": "Yes", "E.8.6.2:Trial being conducted completely outside of the EEA": "No", "E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned": "Argentina\n\n\nAustralia\n\n\nBelgium\n\n\nCanada\n\n\nChile\n\n\nIsrael\n\n\nJapan\n\n\nMexico\n\n\nPortugal\n\n\nRussian Federation\n\n\nSpain\n\n\nSweden\n\n\nTurkey\n\n\nUnited States", "E.8.7:Trial has a data monitoring committee": "Yes", "E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial": "LVLS", "E.8.9.1:In the Member State concerned years": "1", "E.8.9.1:In the Member State concerned months": "10", "E.8.9.1:In the Member State concerned days": "0", "E.8.9.2:In all countries concerned by the trial years": "2", "E.8.9.2:In all countries concerned by the trial months": "1", "E.8.9.2:In all countries concerned by the trial days": "0"}, "F. POPULATION OF TRIAL SUBJECTS": {"F.1.1:Trial has subjects under 18": "No", "F.1.1.1:In Utero": "No", "F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)": "No", "F.1.1.3:Newborns (0-27 days)": "No", "F.1.1.4:Infants and toddlers (28 days-23 months)": "No", "F.1.1.5:Children (2-11years)": "No", "F.1.1.6:Adolescents (12-17 years)": "No", "F.1.2:Adults (18-64 years)": "Yes", "F.1.2.1:Number of subjects for this age range:": "655", "F.1.3:Elderly (>=65 years)": "Yes", "F.1.3.1:Number of subjects for this age range:": "65", "F.2.1:Female": "Yes", "F.2.2:Male": "Yes", "F.3.1:Healthy volunteers": "No", "F.3.2:Patients": "Yes", "F.3.3:Specific vulnerable populations": "Yes", "F.3.3.1:Women of childbearing potential not using contraception": "No", "F.3.3.2:Women of child-bearing potential using contraception": "Yes", "F.3.3.3:Pregnant women": "No", "F.3.3.4:Nursing women": "No", "F.3.3.5:Emergency situation": "No", "F.3.3.6:Subjects incapable of giving consent personally": "No", "F.3.3.7:Others": "No", "F.4.1:In the member state": "9", "F.4.2.1:In the EEA": "72", "F.4.2.2:In the whole clinical trial": "720", "F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)": "None"}, "G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL": {}, "N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED": {"N.:Competent Authority Decision": "Authorised", "N.:Date of Competent Authority Decision": "2016-11-03", "N.:Ethics Committee Opinion of the trial application": "Favourable", "N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion": "", "N.:Date of Ethics Committee Opinion": "2016-11-29"}, "P. END OF TRIAL": {"P.:End of Trial Status": "Completed"}}]